Clinical guide · NAD+ safety

What should be checked before an NAD+ IV?

The practical questions a clinic should resolve before confirming intravenous NAD+ treatment.

For people assessing NAD+ IV safety, suitability and clinical standards.

Clinical guide, not a prescriptionReviewed 22 August 2026How this page is governed

Indonesian nurse monitoring a patient during a supervised NAD+ infusion in a Bali villa — Supervised NAD+ care in Bali.

Context before compound

A proper intake identifies the objective, current symptoms, relevant diagnoses, medication and supplements, allergies, prior IV reactions and previous NAD+ exposure.

Assessment before administration

Identity, consent, baseline vital signs, venous access considerations and the planned monitoring route should be documented. New or urgent symptoms require appropriate medical evaluation, not an elective wellness shortcut.

A plan for intolerance

The team must be able to slow or stop administration, assess symptoms and escalate care when necessary. A villa setting does not remove clinical responsibilities.

After the session

The record should capture dose, duration, tolerance, relevant symptoms and follow-up instructions so the next decision uses the actual response.

Connected clinical library

NAD+, from first question to monitored protocol.

Dose, duration, cost, evidence, tolerance and the clinical checks that connect them.

NAD+ therapy in Bali→NAD+ IV dose guide→NAD+ infusion duration→NAD+ cost in Bali→

Direct answers

Questions to resolve before treatment.

Can everyone receive NAD+ IV?

No. Suitability depends on the individual clinical context and must be reviewed before treatment.

Why can infusion time vary?

Dose, protocol, tolerance and clinical decisions can change the required time. The team should confirm an expected window before booking.

Evidence position

The evidence is applied to the specific clinical question. It supports an individual assessment; it does not replace diagnosis or guarantee an outcome.

Sources used for this page

Human studyGrant et al.: intravenous NAD+ metabolome pilot (2019) ↗Direct six-hour IV NAD+ administration and measured metabolic changes; a small pilot, not proof of broad clinical benefit.Human studyReal-world IV NAD+ and IV NR tolerability pilot (2026) ↗Exploratory infusion duration, symptoms and short-term biomarkers; retrospective data, not an efficacy trial.Scientific reviewVerdin: NAD+ in ageing, metabolism and neurodegeneration (2015) ↗Established NAD+ biology and mechanistic context; it does not establish outcomes from IV therapy.

Accountability

Who stands behind this clinical information.

01 · Editorial ownership

Clinic Terrain Clinical Editorial Team

Prepared and reviewed on 22 August 2026.

02 · Medical accountability

dr. I Wayan Cahyadi Surya Distira Putra, MPH

Clinic Terrain Chief Physician. He leads the medical interpretation of mechanistic, longevity, NAD+ and peptide pathways. The attending physician retains authority over the final clinical plan for each patient.

Chief Physician profile →

03 · Operating and publication standard

Klinik Pratama Cepat Sehat · Bali

Clinical editorial policy →Evidence library →

Your first message · Where you are + what you need help with

Turn what you have learned into a clear question for the clinical team.

Ask about NAD+ suitability →WhatsApp intake open 24/7 · One-minute first-response target